Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial
Among selected high-risk patients who underwent PCI and completed 3 months of dual antiplatelet therapy followed by ticagrelor with or without aspirin, recurrent bleeding was less common than recurrent ischaemic events over 12 months. Analysis of total events indicates that ticagrelor monotherapy continues to be more effective than ticagrelor plus aspirin in reducing bleeding without a signal of ischaemic harm.
Authors
- Davide Cao (ORCID: https://orcid.org/0000-0001-7755-4069)
- Philippe Gabríel Steg (ORCID: https://orcid.org/0000-0001-6896-2941)
- Vijay Kunadian (ORCID: https://orcid.org/0000-0003-2975-6971)
- Bernhard Witzenbichler (ORCID: https://orcid.org/0000-0001-9322-1926)
- E Magnus Ohman
- Samantha Sartori (ORCID: https://orcid.org/0000-0003-0618-9409)
- Roxana Mehran (ORCID: https://orcid.org/0000-0002-5546-262X)
- Stuart Pocock (ORCID: https://orcid.org/0000-0003-2212-4007)
- Samin K. Sharma (ORCID: https://orcid.org/0000-0002-1888-0793)
- Birgit Vogel (ORCID: https://orcid.org/0000-0002-9896-403X)
- Dariusz Dudek (ORCID: https://orcid.org/0000-0001-7804-452X)
- Ran Kornowski (ORCID: https://orcid.org/0000-0002-7708-8253)
- Giora Weisz
- Dominick J. Angiolillo (ORCID: https://orcid.org/0000-0001-8451-2131)
- Upendra Kaul (ORCID: https://orcid.org/0000-0002-4798-7098)
- George Dangas (ORCID: https://orcid.org/0000-0001-7502-8049)
- Shamir R. Mehta (ORCID: https://orcid.org/0000-0003-3258-949X)
- Timothy Collier (ORCID: https://orcid.org/0000-0002-3095-277X)
- Carlo Briguori (ORCID: https://orcid.org/0000-0002-2105-8186)
- Robert Gil (ORCID: https://orcid.org/0000-0002-9041-3313)
- Richard Shlofmitz (ORCID: https://orcid.org/0000-0002-9422-048X)
- Javier Escaned (ORCID: https://orcid.org/0000-0003-4932-0112)
- Usman Baber (ORCID: https://orcid.org/0000-0003-1614-5987)
- David Jonathan Cohen (ORCID: https://orcid.org/0000-0001-9163-724X)
- David J. Moliterno (ORCID: https://orcid.org/0000-0002-2559-4744)
- Gennaro Sardella (ORCID: https://orcid.org/0000-0002-9049-9479)
- Kurt Huber (ORCID: https://orcid.org/0000-0003-1695-3378)
- Mitchell W. Krucoff
Institutions
- Sigmund Freud Privatuniversität Wien (AT)
- Universidad Complutense de Madrid (ES)
- University of London (GB)
- Jagiellonian University (PL)
- Beth Israel Deaconess Medical Center (US)
- NewYork–Presbyterian Hospital (US)
- Harvard University (US)
- University of Kentucky (US)
- Université Paris Cité (FR)
- Columbia University Irving Medical Center (US)
- Policlinico Umberto I (IT)
- Rabin Medical Center (IL)
- New York Hospital Queens (US)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Freeman Hospital (GB)
- Hospital Clínico San Carlos (ES)
- University of Florida (US)
- Clinical Research Institute (US)
- London School of Hygiene & Tropical Medicine (GB)
- Helios Amper-Klinikum Dachau (DE)
- Wilhelminen Hospital (AT)
- St. Francis Hospital (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Clinica Mediterranea (IT)
- Duke Medical Center (US)
- Ministry of Interior and Administration (PL)
- Batra Hospital and Medical Research Centre (IN)
- Central Clinical Hospital (PL)
- Cardiovascular Research Foundation (US)
- University of Oklahoma Health Sciences Center (US)
- Hamilton Health Sciences (CA)
- Newcastle University (GB)
- Sapienza University of Rome (IT)
- Florida College (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- European Heart Journal - Cardiovascular Pharmacotherapy
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1093/ehjcvp/pvae080
- Citations
- 2
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- AstraZeneca
- Icahn School of Medicine at Mount Sinai